RAPT THERAPEUTICS INC (RAPT) Stock Price, Quote, News and Overview
NASDAQ:RAPT - Nasdaq - US75382E1091 - Common Stock - Currency: USD
RAPT Quote, Performance and Key Statistics
RAPT THERAPEUTICS INC
NASDAQ:RAPT (2/5/2025, 8:23:28 PM)
After market: 1.23 +0.02 (+1.65%)1.21
+0.1 (+9.01%)
The current stock price of RAPT is 1.21 USD. In the past month the price decreased by -29.65%. In the past year, price decreased by -95.38%.
RAPT Latest News, Press Releases and Analysis
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...
Progressive, EverQuote upgraded: Wall Street's top analyst calls
Progressive, EverQuote upgraded: Wall Street's top analyst calls
RAPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About RAPT
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Company Info
RAPT THERAPEUTICS INC
561 Eccles Ave
South San Francisco CALIFORNIA 94080 US
CEO: Brian Wong
Employees: 122
Company Website: https://rapt.com/
Investor Relations: https://investors.rapt.com/
Phone: 16504899000
RAPT FAQ
What is the stock price of RAPT?
The current stock price of RAPT is 1.21 USD.
What is the symbol for RAPT THERAPEUTICS INC stock?
The exchange symbol of RAPT THERAPEUTICS INC is RAPT and it is listed on the Nasdaq exchange.
On which exchange is RAPT stock listed?
RAPT stock is listed on the Nasdaq exchange.
Is RAPT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RAPT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RAPT.
Does RAPT stock pay dividends?
RAPT does not pay a dividend.
What is the Price/Earnings (PE) ratio of RAPT?
RAPT does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.77).
What is the Short Interest ratio of RAPT stock?
The outstanding short interest for RAPT is 7.83% of its float.
RAPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RAPT. When comparing the yearly performance of all stocks, RAPT is a bad performer in the overall market: 99.01% of all stocks are doing better.
RAPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RAPT. The financial health of RAPT is average, but there are quite some concerns on its profitability.
RAPT Financial Highlights
Over the last trailing twelve months RAPT reported a non-GAAP Earnings per Share(EPS) of -2.77. The EPS decreased by 3.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.38% | ||
| ROE | -79.43% | ||
| Debt/Equity | 0 |
RAPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to RAPT. The Buy consensus is the average rating of analysts ratings from 13 analysts.